A typical approach might begin with Retatrutide alone for 4 to 8 weeks, add BPC-157 during dose escalation when GI symptoms peak, introduce TB-500 after reaching maintenance Retatrutide doses, and finally add GHK-Cu when significant weight loss begins affecting skin appearance
insufficient human RCT evidence
Unlike full-length growth hormone, AOD-9604 does not upregulate IGF-1, does not induce insulin resistance in reported toxicology models, and does not measurably affect linear growth in adult animal models
While it can still be utilized up to 28 or 30 days in less sensitive research models, studies show that chemical degradation accelerates after the third week
Notably, researchers observed that the rise in p21 levels, a marker of senescence, was independent of p53, indicating that, unlike many previous drugs, AKI603-induced senescence may operate independently of p53 activity [79]